There is a need to develop more sensitive, specific and robust strategies capable of imaging and quantitating therapeutic targets In cancers in vivo. To date, many biological targets and processes remain largely unobserved due to a) lack of affinity ligands, b) mismatches between target abundance and the amount of imaging agent required for target visualization, c) delivery barriers, d) unfavorable pharmacokinetics, e) high background signals, f) the unavailability of appropriate affinity ligands, and/or g) the sheer numbers of targets. The goal of this project is to use a recently developed bioorthogonal platform technology (known as BIND) for the rapid development of intracellular imaging agents such as polo-lil<e kinase (PLK1) and poly-ADP-ribose-polymerase 1 (PARP1), which are key intracellular cancer targets. BIND involves a {4+2} inverse Diels-Alder cycloaddition between fraA7s-cyclooctene (TCO) and a tetrazine (Tz), either attached to an imaging reporter or to a small molecule affinity ligand. BIND is biocompatible, has one of the most favorable reaction kinetics among bioorthogonal reactions, does not require catalysts, works well with small-molecule therapeutic drugs and can be combined with efficient amplifications strategies. This reaction can also be easily incorporated into development strategies for the vast number of existing small molecule affinity ligands for kinases and other intracellular targets. Cell permeable, small-molecule binders for PLK1 and PARP will be modified using TCO/Tz and imaged using complementary TCO/Tzimaging reporters. We will first validate the approach using cell based microscopic imaging, before performing in vivo experiments in mouse models of pancreatic ductal adenocarcinoma (PDAC).
The specific aims are: 1) to develop a library of PLK-1 and PARP1-targeted BIND agents and characterize them biochemically, using live cell imaging and intravital microscopy; 2) to perform target-identification and network analysis using in vivo proteomics (SILAC); and 3) to explore the translational potential using ^^F-labeled agents in gemcitabine and PLKHnhibitor/PARPinhibitor treated mice.

Public Health Relevance

The proposed work will likely lead to more sensitive, rapid and robust generic methods for imaging and quantifying therapeutic targets in cancer. Such technologies will enable physicians to stratify patients into appropriate treatment groups and to detect emerging drug resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086355-13
Application #
8555237
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Project Start
2000-08-09
Project End
2016-06-30
Budget Start
2012-08-22
Budget End
2013-06-30
Support Year
13
Fiscal Year
2012
Total Cost
$107,577
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Miller, Miles A; Askevold, Bjorn; Mikula, Hannes et al. (2017) Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 8:15906
Dubach, J Matthew; Kim, Eunha; Yang, Katherine et al. (2017) Quantitating drug-target engagement in single cells in vitro and in vivo. Nat Chem Biol 13:168-173
Engblom, Camilla; Pfirschke, Christina; Zilionis, Rapolas et al. (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:
Arlauckas, Sean P; Garris, Christopher S; Kohler, Rainer H et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:
Miller, Miles A; Weissleder, Ralph (2017) Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev 113:61-86
Pucci, Ferdinando; Garris, Christopher; Lai, Charles P et al. (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352:242-6
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54
Roy, Jeremy; Kim, Bongki; Hill, Eric et al. (2016) Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun 7:10666
Ghosh, Balaram; Zhao, Wen-Ning; Reis, Surya A et al. (2016) Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation. Bioorg Med Chem Lett 26:1265-1271
Wu, Juwell W; Turcotte, Raphaƫl; Alt, Clemens et al. (2016) Defining Clonal Color in Fluorescent Multi-Clonal Tracking. Sci Rep 6:24303

Showing the most recent 10 out of 314 publications